Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom, Inc. (DXCM) is positioned for growth due to the expanding continuous glucose monitoring (CGM) market, strong first-quarter 2026 performance, and a robust international presence. Key drivers include the expansion into the type 2 non-insulin diabetes population, the successful launch of the G7 15-Day system, and significant growth in international markets. However, the company faces risks such as uncertain CMS reimbursement decisions, rising input costs, and potential moderation of U.S. CGM market growth.
Cadence Stock Trades Near Street’s Target. Here’s Why It Could Go Higher.
Cadence Design Systems (CDNS) exceeded revenue expectations in Q1 2026, raising its full-year guidance to $6.225 billion, driven by a record $8 billion order backlog. Despite a temporary dip in Q1 free cash flow due to acquisition integration costs, analysts anticipate a swift reversal and strong acceleration in free cash flow throughout the year, projecting significant growth by September. TIKR's model suggests a potential 72% total return by December 2030, valuing the stock at $642, contingent on the backlog converting to cash flow and the Hexagon acquisition becoming accretive as expected.
Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.
Intuitive Surgical (ISRG) stock has seen a 26% decline over the last year, primarily due to concerns about slowing elective surgeries and the impact of GLP-1 weight-loss drugs. However, the company is experiencing significant growth in U.S. after-hours procedures, which are non-elective acute care surgeries, growing 31% year-over-year. This expansion into emergency procedures provides a new, resilient growth vector, demonstrating the da Vinci platform's versatility beyond scheduled operations and fueling high-margin recurring revenue.
Evercore ISI Adjusts Price Target on Intuitive Surgical to $430 From $480
Evercore ISI has cut its price target for Intuitive Surgical (ISRG) from $480 to $430. This adjustment reflects a revised outlook from the analyst firm for the medical equipment and technology company. The change was reported on July 6, 2026, at 09:14 am EDT.
Intuitive Surgical stock steadies as investors await the next catalyst.
Intuitive Surgical (ISIN US46120E6023) maintains its strong position in robotic-assisted surgery with its da Vinci platform, listed on Nasdaq. The company's revenue relies on recurring instrument use, service activity, and system sales, making procedure growth and utilization key metrics for investors. With no new company-specific catalysts, the focus remains on its established business model and market context within recurring revenue healthcare technology.
Intuitive Surgical (ISRG) Could Be 20% Undervalued After Its Quarterly Beat
Intuitive Surgical (ISRG) exceeded revenue and earnings expectations after a strong quarterly report, driven by increased procedure volumes and the adoption of its new da Vinci 5 system. Despite a recent share price recovery, the stock is still down year-to-date and over the past year, leading to a valuation discussion on whether it's undervalued. Simply Wall St's narrative suggests ISRG is approximately 20% undervalued with a fair value of $532.46, based on assumptions of steady revenue growth, improving profit margins from recurring sales, and a premium future P/E.
PEN - Penumbra Inc Volatility & Greeks
This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and historical performance over different periods.
Intuitive Surgical (ISRG) Stock Looks Fully Priced After Its 34% Five Year Gain
Intuitive Surgical (ISRG) has seen a 34.4% gain over the past five years, but current valuations suggest the stock is fully priced to expensive. While a Discounted Cash Flow (DCF) model indicates the stock is roughly at fair value, its high P/E ratio compared to the Medical Equipment industry points to overvaluation. Investors are left to weigh whether the company's strong cash flow and robotic surgery ecosystem can justify its premium multiples amidst regulatory scrutiny and competition.
8 Health Care Stocks Whale Activity In Today’s Session
This article identifies significant options trading activity, often referred to as "whale activity," in eight healthcare stocks: DaVita (DVA), Intuitive Surgical (ISRG), Veeva Systems (VEEV), The Cigna Group (CI), Eli Lilly and Co (LLY), Moderna (MRNA), Centene Corp (CNC), and Molina Healthcare (MOH). The analysis details specific call and put options, their sentiment (bullish or bearish), expiration dates, strike prices, total trade prices, open interest, and volume to help traders understand potential market movements. This information is generated by Benzinga's automated content engine to highlight unusual options activity.
Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.
Intuitive Surgical (NASDAQ: ISRG) stock has dropped 28% this year, causing concern among investors and leading several analysts to downgrade their positions. However, Goldman Sachs analyst David Roman argues that the panic is based on a misunderstanding of the company's changes to instrument lifetimes. Roman believes history indicates a recovery, maintaining a price target of $558, suggesting that premium instruments will offset revenue adjustments from extended tool lifespans.
Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.
Intuitive Surgical (NASDAQ: ISRG) stock has dropped 28% this year, causing anxiety among investors and leading several analysts to downgrade their positions. However, Goldman Sachs analyst David Roman increased the stock's price target to $558, arguing that concerns stemming from changes to the company's instrument lifetimes are misunderstood and that historically, such changes have not significantly impacted revenue. The company's underlying business remains robust, with strong growth in procedures and installed surgical systems, though its premium valuation requires careful monitoring.
Ecolab Closes CoolIT Acquisition, Strengthens AI Cooling Portfolio
Ecolab has finalized its acquisition of CoolIT Systems for approximately $4.75 billion, ahead of schedule. This strategic move significantly bolsters Ecolab's footprint in the AI infrastructure market by incorporating CoolIT's direct liquid cooling technologies. The acquisition is expected to drive Ecolab's High-Tech business to $4 billion in annual sales by 2030, enhancing its offerings for semiconductor manufacturing and AI data centers.
Ecolab Closes CoolIT Acquisition, Strengthens AI Cooling Portfolio
Ecolab (ECL) has completed its $4.75 billion acquisition of CoolIT Systems, a direct liquid cooling specialist, strengthening its position in the AI infrastructure market. This acquisition is expected to significantly bolster Ecolab's High-Tech business, with management projecting annual sales of $4 billion by 2030 for the segment. The integration of CoolIT's technology with Ecolab's existing solutions will enable comprehensive offerings for semiconductor manufacturing and AI data centers, supporting long-term growth despite short-term earnings headwinds from acquisition-related costs.
Intuitive Surgical, Inc. Stock 12‑Month Price Target Raised to $573.44, Implies 35% Upside
Intuitive Surgical, Inc.'s average 12-month price target has been increased to $573.44, up from $570.19, based on estimates from 27 analysts. This updated target suggests a potential upside of approximately 35% from the July 2 closing price. The consensus rating from 35 analysts remains a "Buy," with 24 recommending Buy, 10 recommending Hold, and 1 recommending Sell.
Intuitive Surgical Inc (ISRG) Stock Up 5.9% and Still Undervalued -- GF Score: 91/100
Intuitive Surgical Inc (ISRG) saw its stock rise by 5.9% on July 2, 2026, closing at $426.01. Despite this gain, the stock is considered undervalued by GuruFocus, with a GF Value™ of $602.40, indicating a 29.3% margin of safety. The company boasts a strong GF Score™ of 91/100, driven by excellent financial strength, profitability, and growth, although insider selling worth $3.1 million in the last three months warrants attention from investors.
Intuitive Surgical Inc. stock outperforms competitors on strong trading day
Intuitive Surgical Inc. (ISRG) saw its stock price increase by 5.87% to $426.01, outpacing a mixed trading day where the S&P 500 remained largely unchanged and the Dow Jones Industrial Average rose. This marked the second consecutive day of gains for the company's stock. The data is supported by Dow Jones, FactSet, and Automated Insights.
Why Intuitive Surgical (ISRG) Could Beat Earnings Estimates Again
Intuitive Surgical (ISRG) is positioned to beat earnings estimates again, driven by a solid history of exceeding expectations, with an average surprise of 16.32% over the last two quarters. The company's positive Zacks Earnings ESP of +2.78% combined with a Zacks Rank #2 (Buy) further strengthens the prediction for another earnings beat. Investors are advised to consider its Earnings ESP before quarterly releases to increase the odds of success.
Medtronic starts to notify people affected by cyberattack
Medtronic has begun notifying individuals potentially affected by a cyberattack disclosed over two months ago, offering complimentary credit monitoring and identity theft services. The company states there is no evidence the accessed data has been publicly posted, and no impact on product security or patient safety has been identified. This incident follows a string of cyberattacks on other medtech companies, including Stryker, Intuitive Surgical, and iRhythm, highlighting an ongoing industry-wide vulnerability.
Intuitive Surgical Gains as Investors Appear to Position for Mid-July Earnings
Intuitive Surgical (ISRG) saw a 4.0% stock gain today, potentially due to investors anticipating its Q2 earnings call on July 16, 2026. This optimism likely stems from strong Q1 2026 performance, including a 23% revenue increase and significant da Vinci 5 system placements, along with recent product enhancements. The article also details insider trading, hedge fund activity, government contracts, congressional trading, and analyst ratings for ISRG.
Intuitive Surgical Gains as Investors Appear to Position for Mid-July Earnings
Intuitive Surgical (ISRG) saw its stock rise as investors appear to be anticipating its mid-July earnings report. The medical device company's shares gained 2.5%, indicating positive sentiment before the financial disclosure.
Intuitive Surgical (ISRG) Fell on Below-Consensus Forecast
Intuitive Surgical (ISRG) saw a decline after reporting a lower-than-consensus expected outlook for procedure growth in Q1 2026, as noted in Brown Advisory's Large-Cap Growth Strategy investor letter. Despite solid operational performance, macro uncertainty impacted sentiment, leading to a 3.93% one-month return loss and a 26.10% loss over 52 weeks. Brown Advisory remains confident in ISRG's long-term growth but suggests that some AI stocks offer greater short-term promise.
ThoughtSpot Leads 2026 Gartner® Magic Quadrant™ for Analytics, BI Platforms
ThoughtSpot has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Analytics and BI Platforms, acknowledging its vision for Agentic Analytics, trusted AI, and enterprise intelligence at scale. The company believes this positioning validates its investment in conversational analytics, open semantic architectures, and intelligent workflow orchestration, which empower both people and AI agents to derive insights and drive action. ThoughtSpot highlights key business achievements including sustained SaaS growth, the development of Spotter Semantics, and strategic partnerships with Snowflake and Databricks, all contributing to its leadership in the evolving analytics industry.
How Index Shuffle and Da Vinci 5 Momentum Could Reframe Intuitive Surgical’s (ISRG) Investment Story
Intuitive Surgical (ISRG) was removed from the Russell Top 50 Index and added to the Russell 1000 Dynamic Index in late June 2026, a move that does not change its operations but affects fund holdings. This index reshuffle follows a strong Q1 2026 earnings beat, driven by the adoption of its da Vinci 5 system and increased procedure volumes, which has also recently gained clearance for select cardiac procedures in the US. These developments, along with its projected revenue and earnings growth, are poised to reframe its investment narrative, though potential challenges like tighter hospital budgets remain.
How Index Shuffle and Da Vinci 5 Momentum Could Reframe Intuitive Surgical’s (ISRG) Investment Story
Intuitive Surgical (ISRG) was recently moved from the Russell Top 50 Index to the Russell 1000 Dynamic Index, an event that follows a strong Q1 2026 earnings beat driven by da Vinci 5 adoption. This index change, combined with expanding clinical applications for the da Vinci 5 system, is expected to reshape the investment narrative around ISRG, focusing on the speed of hospital adoption and utilization. While the outlook is positive with projected revenue and earnings growth, potential challenges like tighter hospital budgets should also be considered.
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market
20/20 Biolabs (AIDX) outlined its OneTest multi-cancer early detection strategy, which includes a focus on future Medicare reimbursement and a protein biomarker-based test. The company is aligning its strategy with the new Multi-Cancer Early Detection Screening Coverage Act, aiming for Medicare coverage of MCED tests starting in 2028, contingent on FDA authorization and CMS clinical appropriateness. The presentation also detailed an M&A strategy targeting health-and-wellness businesses and included hypothetical revenue projections and a royalty pool for "data investors."
Intuitive Surgical Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Intuitive Surgical Inc. (ISRG) shares rose 1.18% to $402.38 on Wednesday, despite an overall downturn in the stock market where the S&P 500 and Dow Jones Industrial Average both fell. The company's stock closed 33.37% below its 52-week high achieved on January 7th. The article highlights that ISRG underperformed compared to its competitors despite daily gains.
Stryker Vs. Intuitive Surgical: Stryker’s Joint-Replacement Moat Over Intuitive’s Premium Valuation
This article analyzes the Q1 2026 performance of Stryker (SYK) and Intuitive Surgical (ISRG), highlighting their contrasting results. Stryker faced challenges from a cyberattack and restructuring, though its Mako-driven ortho and Inari-boosted vascular segments showed resilience. Intuitive Surgical, while achieving strong revenue growth and EPS, saw its da Vinci procedure growth guidance step down, and its valuation remains significantly higher than Stryker's. The author leans towards Stryker due to its durable exposure and structural compounder profile, despite its recent stock decline.
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospitals and capitalize on an estimated $150 million annual market opportunity. The AMDS device, supported by data showing reduced mortality and adverse events, reinforces Artivion's competitive position in the aortic disease market.
Intuitive Surgical highlights its robotic surgery platform as investors weigh long-term growth prospects
Intuitive Surgical is drawing investor attention with its da Vinci robotic surgery system, focusing on minimally invasive procedures and highlighting its long-term growth profile and competitive position in the medical technology market. The company's business model relies on capital systems, recurring revenue from instrument sales, and service contracts, which contribute to its strong ecosystem. Investors are evaluating factors like procedure growth, new system placements, and product innovation to assess the company's future prospects in the evolving healthcare landscape.
Is Intuitive Surgical Stock a Buy Now After Falling 29% Year to Date?
Intuitive Surgical (ISRG) delivered strong Q1 2026 results, beating Street estimates for revenue and EPS, driven by significant procedure volume growth across its platforms. Despite a 29% year-to-date fall in its stock price, analysts maintain a consensus "buy" rating with a mean target implying 42% upside. TIKR's mid-case model values ISRG at $675 by December 2030, projecting a 70% total return, based on continued utilization of its new da Vinci systems and growth in other platforms, even with headwinds in China and Japan.
Is Avanos Medical (AVNS) Undervalued Or Has Its Strong Run Already Priced In?
Avanos Medical (AVNS) has seen strong stock performance over the last three months and year-to-date, contrasting with longer-term declines and a recent net loss of $74.4 million. The company's current Price-to-Sales (P/S) ratio of 1.6x is below its industry average but above an estimated fair P/S of 1.1x, leading to mixed valuation signals. Investors are advised to consider the key risks and warning signs before making investment decisions.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is positioned for growth due to its innovative Organ Care System (OCS) technology and solid first-quarter 2026 results. Despite a year-to-date stock decline and gross margin pressures, the company's robust pipeline, including next-generation OCS systems and expansion into new organ markets like kidney transplantation, supports its long-term strategy. Analysts maintain a "Hold" rating, while the company continues to invest in expansion and clinical programs.
Advice from a surgical robotics veteran on building a medtech career
Brian Miller, former chief digital officer at Intuitive and now CEO of Sovato, shares insights from his 23-year career in surgical robotics. He advises medtech professionals, especially software engineers, to deeply understand the application and environment where their products will be used. Miller also discusses the evolving dynamics of working at a growing company like Intuitive and the critical mindset required for software development in the medical device industry due to the potential for patient harm.
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
FocalTherics™ has successfully launched its first European commercial endometriosis Focal One® Program at Toulouse University Hospital, treating initial patients with deep infiltrating endometriosis. This initiative marks a significant step for the company's expanded launch strategy across Europe and Latin America, offering a non-surgical, organ-sparing treatment for approximately 38 million women globally affected by the condition. The Focal One Robotic HIFU system uses advanced imaging and high-intensity focused ultrasound to precisely target and ablate endometriosis lesions, aiming to transform the treatment paradigm by minimizing morbidity associated with conventional surgical approaches.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is in a good position for future growth, primarily due to its advanced Organ Care System (OCS) technology and solid first-quarter 2026 results. The company's OCS technology minimizes ischemic injury and improves organ viability, positioning it as a leader in the transplant market. However, TransMedics faces ongoing pressure on its gross margin due to investments in expansion and clinical programs.
Intuitive's robotic surgery use in Korea nearly triples, but insurance coverage still lags
Intuitive Surgical's Korea unit reported a significant increase in robotic surgery procedures, with national adoption tripling since 2019 to account for 16% of major surgeries. Despite this growth and the company's long-standing presence, the lack of national health insurance coverage continues to limit patient access and remains a significant barrier for broader adoption in Korea. Intuitive's general manager also addressed potential Chinese competition, emphasizing the importance of accumulated clinical evidence in robotic surgery.
Is Medtronic (MDT) A Bargain After Renal Denervation Optimism And Strong Revenue Growth?
Medtronic (MDT) has seen recent optimism due to its renal denervation system and strong revenue growth, despite a previous year-to-date share price decline. The stock is considered undervalued with a fair value of $90.37 against a current trading price around $80.98, attracting long-term, income-focused investors due to its consistent growth and 50-year dividend aristocrat status. Investors are encouraged to review the company's fundamentals and analyst forecasts to assess its future potential and risks.
Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy.
Intuitive Surgical (NASDAQ: ISRG) has seen its stock rise more than 400% over the past decade due to its leadership in surgical robotics and strong recurring revenue from services, instruments, and accessories. Despite a recent drawdown of over 30% from its all-time high, the company's powerful "flywheel" model, where an increasing installed base of robots drives high-margin recurring revenue, suggests it remains a strong long-term buy for aggressive growth investors, especially as its current P/E ratio is lower than its five-year average. The article emphasizes that while the stock experiences significant swings, it has historically recovered and reached new highs after similar pullbacks.
Enterprise value to EBIT forward of Intuitive Surgical, Inc. – NASDAQ:ISRG
The article focuses on the enterprise value to EBIT forward for Intuitive Surgical, Inc. (NASDAQ: ISRG). It appears to be a stub or a section focused on financial metrics from a larger financial data platform like TradingView, providing an overview of the company's financial information within the health technology sector. The content primarily highlights the financial statistic for ISRG, indicating a focus on investment analysis.
Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy.
Intuitive Surgical (NASDAQ: ISRG), a leader in surgical robotics with its da Vinci system, has seen its stock rise over 400% in the last decade. Despite a recent 30% drawdown from its all-time high, the company's strong recurring revenue from services, instruments, and accessories makes it an attractive investment. While previously experiencing significant volatility, its current valuation is relatively cheaper compared to its historical P/E ratio, presenting a potential buying opportunity for aggressive growth investors.
Econ Financial Services Corp Has $4.96 Million Stock Position in Medtronic PLC $MDT
Econ Financial Services Corp significantly increased its stake in Medtronic PLC, purchasing an additional 19,204 shares, bringing its total holding to 57,270 shares valued at approximately $4.96 million. This makes Medtronic its 11th largest position, accounting for 2.3% of Econ Financial Services Corp's portfolio. The article also details Medtronic's recent financial performance, including beating earnings estimates, raising its quarterly dividend, and outlines recent insider activity and analyst ratings.
Price to earnings forward of Intuitive Surgical, Inc. – NASDAQ:ISRG
This article provides financial information for Intuitive Surgical, Inc. (NASDAQ: ISRG), specifically focusing on its forward price-to-earnings ratio. It presents a simple table displaying the "Period," "Value," "Change," and "Change %" for this metric.
Price to sales forward of Intuitive Surgical, Inc. – NASDAQ:ISRG
This article provides a financial snapshot of Intuitive Surgical, Inc. (ISRG) focusing specifically on its "Price to sales forward" metric. It appears to be a stub or an incomplete data-driven piece from TradingView, displaying the stock's market data and indicating no trades occurred. The content primarily showcases navigation and copyright information rather than detailed analytical text.
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
Intuitive Surgical, Inc. (ISRG) closed up 1.14% in the latest trading session, outperforming the S&P 500, Dow, and Nasdaq, which all saw declines. Despite a recent monthly stock drop, analysts anticipate positive earnings and revenue growth for the company's upcoming disclosure. ISRG currently holds a Zacks Rank #2 (Buy) and is trading at a premium compared to its industry's Forward P/E ratio.
Intuitive Surgical Inc. stock underperforms Friday when compared to competitors despite daily gains
Intuitive Surgical Inc. (ISRG) stock rose 1.25% on Friday, closing at $404.70, breaking a two-day losing streak. Despite this gain, the stock underperformed compared to the broader market, as both the S&P 500 Index and Dow Jones Industrial Average saw slight declines on the same day.
Enterprise value to revenue forward of Intuitive Surgical, Inc. – NASDAQ:ISRG
This article provides a financial overview of Intuitive Surgical, Inc. (ISRG) on TradingView, focusing on its enterprise value to revenue forward. It lists various sections available for the company's stock information, including financials, news, and technical analysis, within the TradingView platform.
Price to sales forward of Intuitive Surgical, Inc. – LSX:888024
This article focuses on the "Price to sales forward" metric for Intuitive Surgical, Inc. (LSX:888024). It provides a brief overview of the company's financials without specific data points, indicating that the market is closed with no trades. The article is hosted on TradingView and mentions partnerships with ICE Data Services and FactSet for market and reference data.
Price to earnings forward of Intuitive Surgical, Inc. – LSX:888024
This article provides a brief overview of the "Price to earnings forward" metric for Intuitive Surgical, Inc. (LSX:888024) on the TradingView platform. It indicates that the current market for this stock is closed and no trades have occurred for this specific financial metric. The content highlights the availability of financial data and tools for analysis of the company.
SS Innovations International Becomes First Indian Company to Win Top Global Surgical Robotics Honour
SS Innovations International has become the first Indian company to win the Outstanding Company award at the Surgical Robotics Technology (SRT) Industry Awards 2026, a prestigious global honour. The company outperformed several major global players, reinforcing its growing presence and India's capabilities in advanced medical technology. This recognition highlights SS Innovations International's commitment to delivering innovative, accessible, and affordable surgical robotic solutions, further expanding India's global MedTech footprint.
Piper Sandler Highlights Intuitive Surgical (ISRG) on Long-Term Growth Catalysts
Piper Sandler has reiterated an Overweight rating and a $580 price target for Intuitive Surgical (ISRG), based on recent field checks confirming positive sentiment. The firm identifies several growth catalysts for ISRG, including the potential in ambulatory surgery centers, DV5 cardiovascular treatments, and My Intuitive+. Furthermore, recent upgrades to the da Vinci 5 robotic surgical system are expected to enhance Intuitive Surgical's market position, reinforcing the company's strong fundamentals despite prevailing concerns.
